# OnCo record pathos-ai (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/pathos-ai/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "pathos-ai" ;
  schema:name "Pathos AI"@en ;
  schema:description "Pathos AI trains multimodal artificial intelligence models on millions of cancer patients' genomic, imaging, text and outcome records to choose which experimental drugs to develop and which patients to test them in. It has licensed a TROP2/HER3 bispecific antibody-drug conjugate and an oestrogen receptor degrader, and raised a 365 million dollar Series D in 2025."@en ;
  schema:url <https://onco.cc/companies/pathos-ai/>, <https://www.pathos.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.pathos.com/>, <https://www.pathos.com/pathos-ai-secures-365-million-in-series-d-financing-to-advance-oncology-drug-development-through-ai>, <https://www.pathos.com/news> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/nsclc/> ;
  onco:sections <https://onco.cc/fronts/ai-computation/>, <https://onco.cc/fronts/drug-discovery/>, <https://onco.cc/fronts/adcs/> ;
  onco:technologies <https://onco.cc/technologies/pathology-foundation-model/>, <https://onco.cc/technologies/ai-drug-design/>, <https://onco.cc/technologies/bispecific-adc/>, <https://onco.cc/technologies/protac-degrader/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/trop2/>, <https://onco.cc/targets/her3/>, <https://onco.cc/targets/estrogen-receptor/>, <https://onco.cc/targets/met/> ;
  onco:trials <https://onco.cc/trials/nct06785636/> .